These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 26310814)
1. The role of HOXC6 in prostate cancer development. Hamid AR; Hoogland AM; Smit F; Jannink S; van Rijt-van de Westerlo C; Jansen CF; van Leenders GJ; Verhaegh GW; Schalken JA Prostate; 2015 Dec; 75(16):1868-76. PubMed ID: 26310814 [TBL] [Abstract][Full Text] [Related]
2. IgG gene expression and its possible significance in prostate cancers. Liu Y; Chen Z; Niu N; Chang Q; Deng R; Korteweg C; Gu J Prostate; 2012 May; 72(6):690-701. PubMed ID: 22430367 [TBL] [Abstract][Full Text] [Related]
3. Zhou J; Yang X; Song P; Wang H; Wang X Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2715-2720. PubMed ID: 31271305 [No Abstract] [Full Text] [Related]
4. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer. Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060 [TBL] [Abstract][Full Text] [Related]
5. [Mechanism of HOXC6 promoting the progression of prostate cancer by activating the SFRP1/Wnt/β-catenin signaling pathway]. Zheng YJ; Li WM; Zheng LC; Zhou YF; Wang J; Xia WM; Ye WJ; Yu JS Zhonghua Nan Ke Xue; 2024 Jul; 30(7):579-587. PubMed ID: 39212391 [TBL] [Abstract][Full Text] [Related]
6. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia. Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460 [TBL] [Abstract][Full Text] [Related]
7. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy. Zhang L; Guo F; Gao X; Wu Y Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033 [TBL] [Abstract][Full Text] [Related]
8. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms. He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer. Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058 [TBL] [Abstract][Full Text] [Related]
10. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression. Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637 [TBL] [Abstract][Full Text] [Related]
11. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Ramachandran S; Liu P; Young AN; Yin-Goen Q; Lim SD; Laycock N; Amin MB; Carney JK; Marshall FF; Petros JA; Moreno CS Oncogene; 2005 Jan; 24(1):188-98. PubMed ID: 15637592 [TBL] [Abstract][Full Text] [Related]
12. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation. Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612 [TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers. Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626 [TBL] [Abstract][Full Text] [Related]
14. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Zhao Z; Liu J; Li S; Shen W Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463 [TBL] [Abstract][Full Text] [Related]
15. Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection. Javed S; Langley SE BJU Int; 2014 Apr; 113(4):535-40. PubMed ID: 23937390 [TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of HOXC4 and HOXC6 regulated genes and binding sites in prostate cancer cells. Luo Z; Farnham PJ PLoS One; 2020; 15(2):e0228590. PubMed ID: 32012197 [TBL] [Abstract][Full Text] [Related]
17. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225 [TBL] [Abstract][Full Text] [Related]
18. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling. Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458 [TBL] [Abstract][Full Text] [Related]
19. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension? Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478 [TBL] [Abstract][Full Text] [Related]
20. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. Rubicz R; Zhao S; April C; Wright JL; Kolb S; Coleman I; Lin DW; Nelson PS; Ostrander EA; Feng Z; Fan JB; Stanford JL Prostate; 2015 Sep; 75(13):1354-62. PubMed ID: 25990700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]